FDA ends the 50-year long wait for Lupus patients - Benlysta set to become the next blockbuster

Date: March 1, 2011
Pages: 5
Price:
US$ 500.00
License [?]:
Publisher: GlobalData
Report type: Brief Review
Delivery: E-mail Delivery (PDF)
ID: F542C0E015EEN
Leaflet:

Download PDF Leaflet

FDA ends the 50-year long wait for Lupus patients - Benlysta set to become the next blockbuster
FDA ends the 50-year long wait for Lupus patients - Benlysta set to become the next blockbuster

Summary

GlobalData’s report, “FDA ends the 50-year long wait for Lupus patients - Benlysta set to become the next blockbuster” provides key update on the landmark approval of the first lupus drug to be approved by FDA in more than 50 years, HGS/GlaxoSmithKline's Benlysta. It highlights the developmental history of the potential blockbuster drug and its road to approval. This report also highlights the other promising pipeline molecules for lupus.

Scope
  • Benlysta - Developmental Overview, Clinical Trials and Road to Approval
  • Future potential - Safety and efficacy concerns
  • Promising late-stage pipeline for systemic lupus erythematosus
  • Detailed product profiles of three most promising products
Reasons to buy
  • Evaluate the future potential of the first FDA-approved lupus drug in 50 years as a new blockbuster.
  • Understand the latest developments in the field of SLE therapeutics and exploit collaboration and partnership opportunities with the key players involved in the development of promising drugs for lupus.
  • Develop entry strategies to further design product development, marketing and sales strategies in this promising field.
1 TABLE OF CONTENTS

1.1 List of Tables

2 SUMMARY

3 SYSTEMIC LUPUS ERYTHEMATOSUS – OVERVIEW

3.1 The Landmark Approval of Benlysta
  3.1.1 Benlysta – Developmental History
  3.1.2 Benlysta – A potential blockbuster
3.2 Lupus Therapeutics in Pipeline
  3.2.1 Lilly’s anti-BAFF antibody
  3.2.2 Merck Serono’s Atacicept
  3.2.3 UCB’s Epratuzumab

4 APPENDIX

4.1 Methodology
  4.1.1 Coverage
  4.1.2 Secondary Research
  4.1.3 Primary Research
  4.1.4 Expert Panel Validation
4.2 Contact Us
4.3 Disclaimer

LIST OF TABLES

Table 1: Promising SLE Pipeline – 2011

Ask Your Question

FDA ends the 50-year long wait for Lupus patients - Benlysta set to become the next blockbuster
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: